- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06155656
Effects of Pea Proteins With Different Degrees of Processing on Postprandial Metabolism in Healthy Adults
Acute Effects of Pea Proteins With Different Degrees of Processing on Postprandial Metabolism in Healthy Women and Men
Study Overview
Status
Intervention / Treatment
Detailed Description
In a randomized crossover-design, 20 healthy women and men consume 4 test meals containing either 25 g of protein from plant protein ingredients (pea protein concentrate, isolate, or extrudate) or whey protein together with 1 g paracetamol, which is used as a marker for gastric emptying.
During a postprandial period of 6 hours parameters of protein metabolism (e.g. amino acids in plasma and urine), glucose metabolism (plasma glucose, serum insulin) and gastric emptying rate (based on plasma paracetamol) are analysed. Furthermore, subjective hunger/satiety and acceptance of the meals are assed using visual analogue scales. Each intervention arm will be separated by a washout period of at least 7 days.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bonn, Germany, 53115
- University of Bonn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- non-smoking
- metabolically healthy
- normal weight (BMI: 18,5 - 24,9 kg/m2)
- written informed consent
Exclusion Criteria:
- pregnancy, lactation
- hypo- or hypertension
- underweight or overweight/obesity
- food intolerances and allergies (especially milk protein, pea, celery)
- malabsorption syndromes
- gastrointestinal diseases
- thyroid diseases
- diabetes mellitus type 1 and type 2
- impaired kidney or liver function
- anaemia
- blood coagulation disorders
- irregular menstrual cycle
- endometriosis, severe menstrual problems
- hormonal contraception
- regular use of medications (especially habitual use of paracetamol or medications that may interact with paracetamol)
- hypersensitivity to paracetamol
- body weight below 50 kg
- alcohol abuse
- glucose-6-phosphate dehydrogenase deficiency
- Gilbert's syndrome
- vegan diet
- eating disorders (especially anorexia nervosa, bulimia nervosa)
- smoking
- participation in another study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pea concentrate
Participants randomized to receive a soup containing 25 g of protein from pea protein concentrate
|
Ingestion of a soup containing 25 g of protein from pea protein concentrate
|
Experimental: Pea isolate
Participants randomized to receive a soup containing 25 g of protein from pea protein isolate
|
Ingestion of a soup containing 25 g of protein from pea protein isolate
|
Experimental: Pea extrudate
Participants randomized to receive a soup containing 25 g of protein from pea protein extrudate
|
Ingestion of a soup containing 25 g of protein from pea protein extrudate
|
Active Comparator: Whey
Participants randomized to receive a soup containing 25 g of protein from whey protein
|
Ingestion of a soup containing 25 g of protein from whey protein
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amino acid profile in blood
Time Frame: Postprandial period of 5 hours (Time points: fasting (0) and 15, 30, 45, 60, 90, 120, 180, 240 and 300 minutes)
|
Analysis of amino acid profile in plasma (nmol/ml)
|
Postprandial period of 5 hours (Time points: fasting (0) and 15, 30, 45, 60, 90, 120, 180, 240 and 300 minutes)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parameters of protein metabolism in blood I
Time Frame: Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Analysis of urea (mg/dL and mol/L) in blood
|
Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Parameters of protein metabolism in blood II
Time Frame: Postprandial period of 5 hours (Time points: fasting (0) and 60, 120, 180, 240 and 300 minutes)
|
Analysis of nitrogen (mg/dL) in blood
|
Postprandial period of 5 hours (Time points: fasting (0) and 60, 120, 180, 240 and 300 minutes)
|
Parameters of glucose metabolism in blood I
Time Frame: Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Analysis of glucose (mg/dL and mmol/L) in blood
|
Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Parameters of glucose metabolism in blood II
Time Frame: Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Analysis of insulin (nmol/L and pmol/L) in blood
|
Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Gastric emptying rate
Time Frame: Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Analysis of gastric emptying rate based on paracetamol kinetics in blood (µg/mL)
|
Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Hunger/satiety and acceptance of the meals
Time Frame: Postprandial period of 5 hours (Time points: fasting (0) and 15, 30, 45, 60, 90, 120, 180, 240 and 300 minutes)
|
Assessment of subjective hunger/satiety and acceptance of the meals by validated visual analogue scale questionnaires (e.g., 0 = not hungry at all, 10 = very hungry)
|
Postprandial period of 5 hours (Time points: fasting (0) and 15, 30, 45, 60, 90, 120, 180, 240 and 300 minutes)
|
Amino acid profile in urine
Time Frame: Postprandial period of 5 hours
|
Analysis of amino acids in urine (nmol/mL)
|
Postprandial period of 5 hours
|
Uric acid in blood
Time Frame: Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Analysis of uric acid (mg/dL and mmol/L) in blood
|
Postprandial period of 5 hours (Time points: fasting (0) and 30, 60, 90, 120, 180, 240 and 300 minutes)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sarah Egert, Prof PhD, Germany University of Bonn
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AlProPlant-HS1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasma Amino Acid Appearance and Disappearance
-
FrieslandCampinaWageningen University and ResearchCompletedAmino Acid Plasma ProfileNetherlands
-
University of ExeterQuornCompletedPostprandial Plasma Amino Acid AvailabilityUnited Kingdom
-
Sheba Medical CenterUnknownCord Blood Amino Acid Profile | Fetal Amino Acid Profile in Different Gestational Ages | Infant Amino Acid Profile at Day 3 and DischargeIsrael
-
National Taiwan University HospitalCompletedAromatic L-amino Acid Decarboxylase DeficiencyTaiwan
-
Kasper DideriksenUnknownMuscle Protein Synthesis | Meat Protein Supplements | Protein Absorption and Amino Acid AvailabilityDenmark
-
The People's Hospital of GaozhouRecruitingExploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution in Improving Nutritional Status of Maintenance Peritoneal Dialysis PatientsChina
-
Medical University of GdanskCompletedSepsis | Amino Acid Catabolism DisorderPoland
-
ModernaTX, Inc.RecruitingMethylmalonic AcidemiaUnited States, Spain, Canada, Netherlands, France, Australia, United Kingdom
-
LogicBio Therapeutics, IncAlexion Pharmaceuticals, Inc.TerminatedMethylmalonic AcidemiaUnited States
-
ModernaTX, Inc.RecruitingPropionic AcidemiaUnited States, Canada, United Kingdom
Clinical Trials on Pea protein concentrate
-
University of LimerickMarigot Ltd.; Enterprise IrelandCompletedBioavailability of Amino Acids Following Oral Ingestion of Plant-Based Proteins in Young, Healthy MenIreland
-
University of the Incarnate WordCompleted
-
University of ManitobaSaskatchewan Pulse Growers; Alberta Pulse GrowersCompleted
-
Wageningen University and ResearchCompleted
-
Oxford Brookes UniversityRoquette FrèresCompletedHealthyUnited Kingdom
-
University of ManitobaSaskatchewan Pulse Growers; Alberta Pulse GrowersCompletedDiabetes Prevention | Obesity Prevention
-
University of ManitobaSaskatchewan Pulse Growers; Alberta Pulse GrowersCompleted
-
University of ManitobaSaskatchewan Pulse Growers; Alberta Pulse GrowersCompleted
-
Purdue UniversityCompletedAppetitive BehaviorUnited States